HONOLULU, Hawaii — There's new evidence to support a practice that many pulmonologists have been doing empirically anyway: namely, reducing the dose of the antifibrotic medication nintedanib (Ofev) ...

Please provide your email address to receive an email when new articles are posted on . 100 mg of twice-daily nintedanib showed comparable mortality and hospitalization rates as a 150 mg dose.

Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...

While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world ...

HONOLULU -- A reduced-dose regimen of the antifibrotic medication nintedanib (Ofev) held up in real-world clinical practice, an observational study found. Approved for the treatment of idiopathic ...

Please provide your email address to receive an email when new articles are posted on . A pharmacotherapy is needed for patients with small cell lung cancer plus IPF. Patients frequently experienced ...

Antifibrotic treatments for IPF, such as pirfenidone and nintedanib, are associated with significant side effects impacting quality of life. Despite side effects, patients perceive antifibrotics as ...